Systemic lupus erythematosus (SLE)
Marcus Clark, MD
University of Chicago
Chicago, IL, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
Virginia Pascual, MD
Weill Cornell Medical College
New York, NY, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
Iñaki Sanz, MD
Emory University School of Medicine
Atlanta, GA, United States
Disclosure information not submitted.
The heterogeneity of SLE presents a significant challenge in the treatment of the disease and the development of successful clinical trials. Investigators from NIAID’s Autoimmunity Centers of Excellence will present progress into the characterization of SLE heterogeneity and pathogenesis. Presentations will cover progress made in defining SLE disease states based on molecular features, including transcriptional and epigenetic analysis, in situ analysis of renal biopsies, and exosome analysis. Advances in the development of high throughput assays requiring small cell numbers, increasing the applicability of these techniques to the clinic, will be shared. Presenters will discuss findings on novel cellular pathways active in SLE disease pathogenesis, pointing to potential therapeutic targets. Finally, presenters will discuss progress towards screening assays to predict the response to therapy, flare onset, and the development of organ-specific complications.
Speaker: Iñaki Sanz, MD – Emory University School of Medicine
Speaker: Virginia Pascual, MD – Weill Cornell Medical College
Speaker: Marcus Clark, MD – University of Chicago
